| Autor: |
Usmani SZ; Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC; and., Seifter E; Johns Hopkins University School of Medicine, Baltimore, MD. |
| Abstrakt: |
Competing Interests: Conflict-of-interest disclosure: S.Z.U. has received research funding from Amgen, Array Biopharma, BMS, Celgene, Janssen, Pharmacyclics, Sanofi, and Takeda; consulted for Abbvie, Amgen, BMS, Celgene, Janssen, Takeda, Sanofi, and SkylineDx; and been affiliated with the Speaker’s Bureau for Amgen, Celgene, Janssen, and Takeda. |
